**e-table 8. Ongoing clinical trials**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Serial****number** | **Name of the trial** | **NCT number** | **Sponsor/Collaborators** | **Country** | **Study Design** | **Number enrolled** | **Interventions** | **Outcomes** | **Status** |
| 1 | Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff | NCT04723459 | South Valley University | Egypt | Interventional | 150  | * Ivermectin mask
 | * Number of persons in each group who Complain of any suspected Symptoms
* Number of persons in each group who are diagnosed as COVID-19 patients
 | Recruiting |
| 2 | Inhaled Ivermectin and COVID-19(CCOVID-19) | NCT04681053 | Mansoura University | Egypt | Interventional | 80 | * Ivermectin Powder
 | * Rate of virological cure by RT-PCR
* Resolution of pneumonia
 | Recruiting |
| 3 | Ivermectin in the treatment of COVID-19 patients | NCT04723459 | Ministry of Health and Population, Egypt | Egypt | Interventional | 100 | * Ivermectin
 | * Rate of viral clearance in comparison to other treatment protocols
* Evaluate the role of ivermectin as a line of treatment for COVID-19
 | Recruiting |
| 4 | An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization | NCT04729140 | Max Health, Subsero Health | USA | Interventional | 150 | * Ivermection,
* Doxycycline
* Placebo
 | * Assessment of Hb, WBC, HcT, Platelet Count, Na,Cl,Co2 levels,
* Admission rate to the hospital secondary to respiratory illness related to COVID-19,
* Total duration of symptoms secondary to respiratory illness related to COVID-19
 | Recruiting |
| 5 | COVidIVERmectin: Ivermectin for Treatment of Covid-19 | NCT04438850 | IRCCS Sacro Cuore Don Calabria di Negrar and Istituto Di Ricerche Farmacologiche Mario Negri | Italy and Spain | Interventional | 102 | * Ivermectin
* Placebo
 | * SADR
* Viral load
* Trend viral load
* Clinical resolution
* Viral clearance
* Virological clearance
* Hospitalization rate
* Severity score
 | Recruiting |
| 6 | Ivermectin to Prevent Hospitalizations in COVID-19 | NCT04529525 | Instituto de Cardiología de Corrientes | Argentina | Interventional | 500 | * Ivermectin
* Placebo
 | * Percentage of Hospitalization of medical cause in patients withCOVID-19 in each arm
* Time to hospitalization
* Percentage of use of invasive mechanical support in each arm
* Time to invasive mechanical ventilation support
* Percentage of dialysis in each arm
* All-cause mortality
* Negative of the swab at 3±1 days and 12±2 days after entering the study
* Incidence of Treatment Emergent Adverse Events
 | Recruiting |
| 7 | Study in COvid-19 Patients With ivermectin (CORVETTE-01) | NCT04703205 | Kitasato University | Japan | Interventional | 240 | * Ivermectin
* Placebo
 | * Period until the COVID-19 PCR test becomes negative
 | Recruiting |
| 8 | Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment | NCT04673214 | Gilberto Cruz Arteaga | Mexico | Interventional | 62 | * Azithromycin
* Ivermectin
* Ribaroxaban
* Paracetamol
 | * Estimate clinical symptoms by days of follow-up
* To assess adverse drug reactions by days of follow-up
 | Recruiting |
| 9 | Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 | NCT04429711 | Sheba Medical Center | Israel | Interventional | 100 | * Ivermectin
 | * Viral clearance at day 6
* Viral shedding
* Duration of Symptoms
* Clearance time
 | Recruiting |
| 10 | Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19 | NCT04716569 | South Valley University | Egypt | Interventional | 150 | * Ivermectin intranasal spray
 | * Progression of covid 19 clinical picture
 | Recruiting |
| 11 | Efficacy of Ivermectin in outpatients with non-severe COVID-19 | NCT04834115 | Universidad Nacional de Asuncion | Paraguay | Interventional | 400 | * Ivermectin tablets
 | * Primary-proportion of patients with hospitalization criteria
* Secondary- 1)proportion of patients with COVID-19 signs and symptoms 2)proportion of cohabitants who had COVID-19 after the index case 3)drug-related adverse events 4)Levels of IgG for SARS-CoV-2
 | Recruiting |
| 12 | Ivermectin in Adults With Severe COVID-19. | NCT04602507 | CES University | Colombia | Interventional | 100 | * Ivermectin plus routine care
 | * Admission to the intensive care unit
* Hospital length of stay
* Mortality rate
* ICU length of stay
* Length of stay in ventilator time
* Adverse effects of ivermectin
 | Recruiting |
| 13 | Ivermectin as a Novel Therapy in COVID-19 Treatment | NCT04403555 | Tanta University | Egypt | Interventional | 160 | * Ivermectin plus standard of care
 | * The number of patients with improvement or mortality
 | Recruiting |
| 14 | Ivermectin in Treatment of COVID-19 | NCT04445311 | Zagazig University | Egypt | Interventional | 100 | * Ivermectin
 | * Time to be symptoms free
* Need hospital admission
* Need mechanical ventilation
* Length of stay
* Mortality
 | Recruiting |
| 15 | Efficacy of Ivermectin in COVID-19 | NCT04392713 | Combined Military Hospital, Pakistan | Pakistan | Interventional | 100 | * Ivermectin
 | * Negative PCR
* Need for mechanical ventilation
 | Recruiting |
| 16 | The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment | NCT04351347 | Tanta University | Egypt | Interventional  | 300 | * Ivermectin plus Nitazoxanide
 | * Number of patients with improvement or died
 | Recruiting |
| 17 | Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study | NCT04373824 | Max Healthcare Institute Limited | India | Interventional | 50 | * Ivermectin
 | * Effect of ivermectin on the eradication of virus
 | Recruiting |
| 18 | Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms | NCT04727424 | Cardresearch | Brazil | Interventional  | 2724  | * FluvoxamineMaleate 100 MG [Luvox]
* MetforminExtended ReleaseOral Tablet
* IvermectinTablets
* Placebo
 | * Change in viral load on day 03 and 07 after randomization
* Time to > 50% clinical improvement
* Time to hospitalization
* Days with symptoms
* All cause hospitalizations
* COVID-19 hospitalizations
* All-Cause Death
* Cardiovascular death
* Respiratory death
* Promis Global-10 scale
* WHO ordinal scale for clinical improvement
* Percentage of adherence on Study drug
 | Recruiting |
| 19 | Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 (IvAzCol) | NCT04399746 | Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado | Mexico | Interventional  | 30  | * Ivermectin
* Azithromycin
* Cholecalciferol
 | * Viral clearance
* Symptoms duration
* SpO2, SpO2/FiO2
 | Recruiting |
| 20 | Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection (IDRA-COVID19) | NCT04435587 | Mahidol University | Thailand | Interventional  | 80  | * Ivermectin Pill
* Combined ART/ hydroxychloroquine
 | * Adverse event rates
* Efficacy for shortening duration of SAR-CoV2 detection by PCR
* Antibody detection rates
 | Recruiting |
| 21 | Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients (SIZI-COVID-PK) | NCT04472585 | Sohaib Ashraf  | Pakistan | Interventional  | 60  | * Ivermectin Injectable Solution
* Injectable Placebo
* Zinc
* Placebo empty capsule
 | * Time needed to turn positive COVID-19 PCR to negative
* Time taken for alleviation of symptoms
* Severity of symptoms
* Mortality
 | Recruiting |
| 22 | Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19 (SAINT-PERU) | NCT04635943 | Universidad Peruana Cayetano Heredia Barcelona Institute for Global Health | Peru | Interventional  | 68 | * Ivermectin
* Placebo
 | * Proportion of patients with a positive SARS-CoV-2 PCR
* Mean viral load
* Fever and cough progression
* Seroconversion at day 21
* Proportion of drug-related adverse events
* Levels of IgG, IgM and IgA
* Frequency of innate immune cells
* Frequency SARS-CoV-2- specific CD4+ and CD8+ T cells
* Results from cytokine Human Magnetic 30-Plex Panel
* Presence of intestinal helminths
 | Recruiting |
| 23 | Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection (TITAN) | NCT04447235 | Instituto do Cancer do Estado de São Paulo | Brazil | Interventional  | 176 | * Placebo
* Ivermectin
* Losartan
 | * Incidence of severe complications due COVID-19 infection
* Incidence of Severe Acute Respiratory Syndrome
* Adverse events
* Overall survival
 | Recruiting |
| 24 | Comparative therapeutic efficacy and safety of different antiviral and anti inflammatory drugs in COVID-19 patients | NCT04779047 | Beni-Suef University | Egypt | Interventional  | 150 | * Remdesivir
* Hydroxychloroquine
* Tocilizumab
* Lopinavir/ Ritonavir
* Ivermectin
 | * Percentage of clinical cure in each arm
 | Recruiting |
| 25 | Novel Agents for Treatment of High-risk COVID-19 Positive Patients | NCT04374019 | Susanne Arnold University of Kentucky | United States | Interventional  | 240 | * Ivermectin
* Camostat Mesilate
* Dietary Supplement: Artemesia annua, Artesunate
 | * Clinical Deterioration
* Change in Viral Load
* Rate of Organ Failure
* Progression to ICU Care or Ventilation
* Change in Clinical Status
* Mortality
* Rate of severe adverse events
* Oxygen-free days
* Ventilator-free days
* Vasopressor-free days
* ICU-free days
* Hospital-free days
* Patients meeting Hy's Law criteria
* Liver Function
* Heart Function
 | Recruiting |
| 26 | Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis | NCT04384458 | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | Brazil | Interventional  | 400 | * Hydroxychloroquine
* Ivermectin
 | * Proportion of participants in whom there was a positivity for SARS CoV-2
* Participants who developed mild, moderate, or severe forms ofCOVID-19
* Measurement of the QT interval
* Widening of the corrected QT interval or with changes in heart rate on the ECG
* Comparison of hematological and biochemical parameters
* Occurrence of adverse events
* Assessment of COVID-19 symptom severity
* Proportion of participants who discontinue study intervention
* Proportion of participants who required hospital care
* Proportion of participants who required mechanical ventilation.
 | Recruiting |
| 27 | A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19 | NCT04431466 | Universidade Federal de Sao Carlos | Brazil | Interventional | 64 | * Ivermectin
* Standard treatment for COVID-19
 | * Time to undetectable SARS-CoV-2 viral load in the nasopharyngeal swab
* Viral load variation in the nasopharyngeal swab
* Proportion of patients with undetectable SARSCoV-2 viral load in the nasopharyngeal swab
* Proportion of patients with clinical improvement.
 | Recruiting |
| 28 | Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia | NCT04703608 | London School of Hygiene and Tropical Medicine | Gambia | Interventional  | 1200 | * Ivermectin
* ASP (Aspirin Parallel Assignment)
* Placebo
 | * Cohort 1 Index Case: Percentage of patients with COVID-19 associated mild disease/moderate pneumonia progressing to severe pneumonia.
* Cohort 1 Household contacts: Percentage of HH members that get infected with SARS-CoV-2
* Cohort 2: Percentage of COVID-19 associated severe pneumonia patients worsening their condition
* Cohort1 Index cases: Days from recruitment to virological clearance
* Days from recruitment until clinical recovery
* IgG geometric mean titre (GMT) at day 14 and 28 after recruitment-Household contacts IgG geometric mean titre (GMT) at day 14 after recruitment -Percentage of HH members infected that develop COVID19 symptoms -Cohort 2 - Hours from recruitment to hospital discharge-Hours of duration on oxygen supplementation
* Death ratio during hospitalization
* Death ratio at D28 and D90
* Occurrence of clinical thrombotic and embolic events
* Occurrence of clinical episodes of gastrointestinal bleeding
* Change in CRP and D-Dimer levels
* Persisting breathlessness at 28 days and 90 days after
* Self-reported health at 28 days and 90 days
 | Recruiting |
| 29 | Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19 | NCT04632706 | MedinCell S.A MAC Clinical Research | United Kingdom | Interventional (Randomized, double blinded) | 24 | * Ivermectin
* Placebo
 | • Pharmacokinetic concentrations:- Maximum Plasma Concentration [Cmax]- Time to Reach Cmax [Tmax]- Trough Plasma Concentration [Ctrough]- Area under the plasma concentration-time curve from zero to 24 hours [AUC0-24h] - Area under the plasma concentration-time curve from zero to 48 hours [AUC0-48h - Average Plasma Concentration at steady state [Cavg ss] - Apparent Terminal Half-Life [T1/2] - Number of participants with treatment emergent adverse events (TEAEs) •Safety and Tolerability:- Number of participants with abnormal electrocardiograms (ECG) - Number of participants with abnormal clinical neurological exam - Number of participants with abnormal urine and/or blood test- Number of participants with abnormal physical exams | Recruiting |
| 30 | Trial of Combination Therapy to Treat COVID-19 Infection | NCT04482686 | ProgenaBiome Topelia Therapeutics | United States | Interventional  | 30 | * Ivermectin
* Doxycycline
* Hcl
* Zinc
* Vitamin D3
* Vitamin C
 | * Time to Non-Infectivity by RT-PCR
* Time to Symptom progression in days
* Time to Symptom improvement
* Efficacy of Treatment as measured by Titer
* Efficacy of Treatment as measured by RT-PCR, D-Dimer, ProCalcitonin, CRP, Ferritin, Liver Enzymes, CBC, Electrolyte Levels
* Treatment Related Adverse Events
 | Recruiting |
| 31 | Risk Stratification of COVID-19 Using Urine Biomarkers | NCT04681040 | National Center for Global Health and Medicine, Japan | United States, Brazil, Denmark, Japan, Tokyo, Japan, Philippines | Observational, Prospective Cohort | 1000 | - | * Risk Stratification of COVID-19 Participants Using Urine Biomarkers
* Prediction of COVID-19 Treatment by Urine LFABP
* Increase of O2 support, hospital days, worsening of chest X-ray and CT, and survival rate, at 14 and/or 30 days
* Comparison of Risk Stratification with Other Biomarkers
 | Recruiting |
| 32 | Ivermectin Nasal spray for COVID-19 patients | NCT04510233 | Tanta University | Egypt | Interventional | 60 | * Ivermectin (oral and nasal)
 | * PCR of SARS-Cov2 RNA
 | Not yet recruiting |
| 33 | Outpatient use of Ivermectin | NCT04530474 | Temple University | USA | Interventional | 200 | * Ivermectin
 | * Clinical improvement
 | Not yet recruiting |
| 34 | The (HD)IVACOV Trial (The High-Dose Ivermectin Against COVID-19 Trial) | NCT04712279 | Corpometria Institute | Brazil | Interventional | 294 | * Ivermectin
* Hydroxychloroquine
 | * WHO clinical progression scale
* Clinical Improvement
* Time-to-recovery
* Viral load
* Positivity rate of rtPCR-SARS-CoV-2
* Duration of fatigue and anosmia
* Overall duration of clinical manifestations
* Proportion of subjects needing
* Additional drugs or interventions
* oxygen use
* high-flow oxygen therapy or non-invasive ventilation
* Proportion of hospitalizations
* Proportion of mechanical ventilation use
* Proportion of pressors use
* Proportion of deaths
* Proportion of post-COVID mental and physical symptoms
* Proportion of post-COVID overall symptoms
* Duration of new oxygen use, hospitalization and mechanical ventilation
* Proportion of increased CRP, d-dimer and eosinophils
* Proportion of decrease in ESR
* Disease duration
* Change in viral load from baseline to Day 5
 | Not yet recruiting |
| 35 | Ivermectin and Nitazoxanide Combination Therapy for COVID-19 | NCT04360356 | Tanta University | Egypt | Interventional | 100 | * Ivermectin plus Nitazoxanide
 | * Number of Patients with COVID-19-negative PCR
* Number of patients with improved respiratory rate
* Number of patients with improved PaO2
* Number of patients with normalized Serum IL6
* Number of patients with normalized Serum TNFα
* Number of patients with normalized Serum iron
* Number of patients with normalized Serum ferritin
* Number of patients with normalized PT-INR
* Number of patients with normalized complete blood count,
* Mortality rate among treated patients
 | Not yet recruiting |
| 36 | Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19 | NCT04551755 | Bangladesh Medical Research Council (BMRC | Bangladesh | Interventional  | 188 | * Ivermectin and Doxycycline
* Placebo
 | * Time to outcome measure of fever (<100.40F)and cough
* Negative RT-PCR test on day 5 of treatment
 | Not yet recruiting |
| 37 | Safety and efficacy of low dose aspirin/ivermectin combination therapy for treatment of COVID-19 patients (IVCOM) | NCT04768179 | * Makarere University
* Ministry of Health, Uganda
* Mbarara University of Science and Technology
* Joint Clinical Research Center
 | Uganda | Interventional | 490 | * Ivermectin
* ASA
* Standard of therapy
 | * SARS COV 2 Viral clearance
* World Health Organization COVID-19 ordinal improvement score
* Clinical recovery
* Spectrum and severity of adverse events
* Maximum Plasma concentration
* Minimum Plasma concentration
* Area Under the Curve

  | Not yet recruiting |
| 38 | Effectiveness and Safety of Ivermectin for the Prevention of Covid 19 Infection in Colombian Health Personnel | NCT04527211 | Javeriana University | Colombia | Interventional  | 550 | * Ivermectin
 | * Clinical development of covid-19 disease during the intervention period
* Seroconversion
* Hospitalization requirement
* Intensive Care Unit Requirement
* Safety of the intervention
 | Not yet recruiting |
| 39 | New Antiviral Drugs for Treatment of COVID-19 | NCT04392427 | Mansoura University | Egypt | Interventional  | 100 | * Nitazoxanide,Ribavirin andIvermectin for aduration of sevendays
 | * Negative test result for COVID-19
 | Not yet recruiting |
| 40 | Study the efficacy and therapeutic safety of Ivermectin (SAINTBO) | NCT04836299 | * Universidad Mayor de San Simón
* Barcelona Institute for Global Health
* Université Catholique de Louvain
 | Bolivia | Interventional | 90 | * Ivermectin
* Placebo
 | * Evolution of viral load
* Clinical remission
* Clinical signs of toxicity
* Need for supplemental oxygen
* Hospital stay
* Need for mechanical ventilation
 | Not yet recruiting |
| 41 | Efficacy, Safety and Tolerability of Ivermectin in Subjects Infected With SARS-CoV-2 With or Without Symptoms | NCT04407507 | Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V. | - | Interventional  | 66 | * Ivermectin
* Placebo
 | * Participants with a disease control status defined as no disease progression to severe
 | Not yet recruiting |
| 42 | Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic | NCT04460547 | Qassim University | - | Observational, Retrospective Cohort | 200 | * Convalescent Plasma Transfusion
* Hydroxychloroquine
* DAS181
* Ivermectin,
* Interferon Beta-1A
 | * Geographical distribution of the interventional and observational studies
* Monthly Research study completion rate as per geographic distribution of the Research
* Statistical correlation of the interventional, Observational, drug based interventional, diagnostic test based interventional and device based interventional studies
 | Not yet recruiting |